Achievements

• Translate the results of surveillance of antimicrobial resistance and promote the proper use of antibiotic to reduce the costs of health insurance and improve healthcare quality.
• Identification the major types of Klebsiella penumoniae responsible for the development of liver abscess and endophthalmitis.
• Studies on the molecular genotyping and epidemiological surveillance of mycobacterium tuberculosis reveal distinct modes of transmission of tuberculosis in different populations in Taiwan.
• Studies on pathogenesis of tumor viruses (HBV, HCV, and EBV) reveal inflammatory, immunoregulatory, and ER stress factors as key therapeutic targets.
• Completion of phase I clinical trial of EV71 and H5N1 vaccine , the technology has been transferred to the industry.
• Completion of pre-clinical study of H7N9 vaccine and the technology has been transferred to the industry.
• The approval of the investigational new drug application for phase I clinical trial of MGB vaccine has been gained.
• Bioproduction plant has received a PIC/S GMP certificate allowing contract manufacture of BCG and antivenom for Centers for Disease Control (Taiwan).
• A platform technology for the efficient production of recombinant lipoprotein with high immunogenicity for novel subunit vaccines was established by National Institute of Infectious Disease and Vaccinology (NIIDV). Several targets were ready go for industrialization, including prophylactic vaccines against Dengue virus, Clostridium difficile, broad-spectrum pneumococcal vaccine and therapeutic vaccine against Human papillomavirus associated tumors.
• The hSCARB2-transgenic mice are approved to be used in studying EV71 and CVA16 to develop effective or vaccines preventing diseases associated with enteroviruses.